The global liquid biopsy market is projected to register a CAGR of 18.91% over the forecast period, and is anticipated to generate revenue of $4918.5 million by 2028. The base year considered for the market study is 2020, and the forecasted years are from 2021 to 2028.

GLOBAL LIQUID BIOPSY MARKET FORECAST 2021-2028

Global Liquid Biopsy Market by Therapeutic Application (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma Cancer, Other Types of Cancer, Non-oncology Application) by Clinical Application (Treatment Monitoring, Prognosis and Reoccurrence Monitoring, Treatment Selection, Diagnosis and Screening) by Biomarker Type (Nucleic Acid, Protein, Extracellular Vesicles, Cells) by Analysis Platform (Ngs, Microarray, Pcr, Proteomics, Other Analysis Platforms) by Analysis Purpose (Early Detection/screening, Therapy Guidance, Monitoring, Diagnosis) by product (Circulating Tumor Dna (Ctdna), Circulating Tumor Cells (Ctcs), Cell-free Dna (Cfdna), Extracellular Vesicles and Others) by End-user (Physicians’ Office Laboratories, Hospitals, Clinical Diagnostic Laboratories) and by Geography.

Request free sample

Report Summary

The global liquid biopsy market is projected to register a CAGR of 18.91% over the forecast period, and is anticipated to generate revenue of $4918.5 million by 2028. The base year considered for the market study is 2020, and the forecasted years are from 2021 to 2028.

Liquid biopsy is a non-invasive method, which helps determine and monitor cancer and other diseases. In order to perform a liquid biopsy, blood or other fluids, such as urine, are collected and sequenced, or analyzed by using next-generation sequencing (NGS) systems and assays.liquid biopsy markets

To know more about this report, request a free sample copy

Key factors propelling the global liquid biopsy market growth:

  • Rising government initiatives
  • Incidence of cancer cases in the older populace
    • The rising older population is one of the major factors attributed to the increasing adoption of liquid biopsy tests.
    • Aging deteriorates the body’s immune system. As a result, most people aged 60 years and above are susceptible to chronic diseases like cancer and cardiovascular diseases.
  • Shifting demand of consumers for diagnostic centers
  • Non-invasive nature of liquid biopsy testing
  • Emergence of tissue/tumor-agnostic drugs
  • Patients’ preference for liquid biopsy testing
  • Technological advancements

Major growth restraining factors:

  • Lack of consensus on standard operating procedures (SOPs)
  • Poor compensation structures
  • High cost of the test
    • A critical problem witnessed in developing countries is the patients’ failure to afford high-cost tests.
    • In contrast, Americans pay excessively high prices for adequate health treatment and different kinds of care. For the majority, including people with proper insurance coverage, the rising out-of-pocket expenses are a surprising fact.
  • Reimbursement issues
  • Dearth of skilled professionals

The report scope of the global liquid biopsy market includes the segmentation analysis of therapeutic application, clinical application, biomarker type, analysis platform, analysis purpose, product, and end-user. One of these segments is further classified to provide a detailed analysis of the studied market.

Market by Therapeutic Application:

  • Lung Cancer
    • The lung cancer segment dominated the therapeutic application category in 2020.
    • In terms of lung cancer, identifying the molecular profile of the tumor plays a vital role in determining the treatment’s approaches.
    • However, a conventional tissue biopsy cannot be the advisable method, as recurrent biopsies are invasive and involve blood and tissue loss.
  • Prostate Cancer
    • Prostate cancer is the leading therapeutic application.
    • Prostate cancer is the most common cancer among men.
    • Generally, the cancer type is diagnosed in men over 40 years, and the susceptible patient risk for the same increases rapidly after the age of 50.
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma Cancer
  • Other Types of Cancer
  • Non-Oncology Application

Geographically, the global liquid biopsy market has been segmented based on four major regions, which includes:

  • North America: The United States and Canada
    • North America is set to hold the highest market share by 2028.
    • Moreover, owing to the increasing number of cancer cases, the demand for liquid biopsy in North America is expected to increase in the upcoming years.
    • The United States and Canada possess superior biopsy technologies specialized in detecting diseases at early stages. This aspect can significantly reduce the mortality rates across these countries.
  • Europe: Italy, the United Kingdom, Germany, France, Russia, Poland, Belgium, and Rest of Europe
  • Asia-Pacific: India, China, South Korea, Australia & New Zealand, Japan, Thailand, Indonesia, Vietnam, and Rest of Asia-Pacific
    • The Asia-Pacific offers lucrative opportunities for the liquid biopsy market, and is anticipated to register the highest growth rate during the forecast period.
    • An increase in healthcare expenditure and the surging awareness related to the use of liquid biopsy have propelled the growth of the market.
  • Rest of World: Latin America, the Middle East & Africa

Key players in the global liquid biopsy market: 

  • Agilent Technologies Inc
  • Becton, Dickinson and Company (BD)
  • Hoffmann-La Roche
  • GRAIL
  • Qiagen NV
  • Others

Key strategies adopted by some of these companies:

In January 2021, Adaptive Biotechnologies collaborated with AstraZeneca in charting the immune response to the cancer antigens to possibly inform the expansion of novel therapeutics and diagnostics.

Key findings of the global liquid biopsy market:

  • New players approach venture capitalists, in order to enter niche markets, such as, liquid biopsy.
  • Direct-to-consumer testing, especially for small start-up enterprises, enables business expansion.
  • The rising number of cancer patients plays an important role in augmenting the global liquid biopsy market growth.
  • Emerging economies continue to observe the increased adoption of liquid biopsy.

Frequently Asked Questions and Answers (FAQs):

  • What is the impact of the older populace on the global liquid biopsy market?

A: The incidence of breast cancer and colorectal cancer is increasing, on account of the rising geriatric population. This factor is projected to drive the global liquid biopsy market during the forecast period.

  • How does liquid biopsy help provide customized treatments?

A: A liquid biopsy plays an important role in the development of customized treatments for patients. It provides vital real-time information about the tumor profile and helps decide the further steps in the treatment.

Table of Contents

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • MARKET DEFINITION
    • KEY DRIVERS
      • RISING GOVERNMENT INITIATIVES
      • INCIDENCE OF CANCER CASES IN OLDER POPULACE
      • SHIFTING DEMAND OF CONSUMERS FOR DIAGNOSTIC CENTERS
      • NON-INVASIVE NATURE OF LIQUID BIOPSY TESTING
      • EMERGENCE OF TISSUE/TUMOR-AGNOSTIC DRUGS
      • PATIENTS’ PREFERENCE FOR LIQUID BIOPSY TESTING
      • TECHNOLOGICAL ADVANCEMENTS
    • KEY RESTRAINTS
      • LACK OF CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPS)
      • POOR COMPENSATION STRUCTURES
      • HIGH COST OF THE TEST
      • REIMBURSEMENT ISSUES
      • DEARTH OF SKILLED PROFESSIONALS
  1. KEY ANALYTICS
    • PORTER’S FIVE FORCES ANALYSIS
      • THREAT OF NEW ENTRIES
      • THREAT OF SUBSTITUTIONS
      • BUYERS POWER
      • SUPPLIERS POWER
      • COMPETITIVE RIVALRY
    • IMPACT OF COVID-19 ON LIQUID BIOPSY MARKET
    • KEY LIQUID BIOPSY INITIATIVES
    • REGULATORY FRAMEWORK
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • KEY INVESTMENT INSIGHTS
  2. MARKET BY THERAPEUTIC APPLICATION
    • LUNG CANCER
    • BREAST CANCER
    • PROSTATE CANCER
    • COLORECTAL CANCER
    • MELANOMA CANCER
    • OTHER TYPES OF CANCER
    • NON-ONCOLOGY APPLICATION
  3. MARKET BY CLINICAL APPLICATION
    • TREATMENT MONITORING
    • PROGNOSIS AND REOCCURRENCE MONITORING
    • TREATMENT SELECTION
    • DIAGNOSIS AND SCREENING
  4. MARKET BY BIOMARKER TYPE
    • NUCLEIC ACID
    • PROTEIN
    • EXTRACELLULAR VESICLES
    • CELLS
  5. MARKET BY ANALYSIS PLATFORM
    • NGS
    • MICROARRAY
    • PCR
    • PROTEOMICS
    • OTHER ANALYSIS PLATFORMS
  6. MARKET BY ANALYSIS PURPOSE
    • EARLY DETECTION/SCREENING
    • THERAPY GUIDANCE
    • MONITORING
    • DIAGNOSIS
  7. MARKET BY PRODUCT
    • CIRCULATING TUMOR DNA (CTDNA)
    • CIRCULATING TUMOR CELLS (CTCS)
    • CELL-FREE DNA (CFDNA)
    • EXTRACELLULAR VESICLES AND OTHERS
  8. MARKET BY END-USER
    • PHYSICIANS’ OFFICE LABORATORIES
    • HOSPITALS
    • CLINICAL DIAGNOSTIC LABORATORIES
  9. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • UNITED STATES
        • CANADA
    • EUROPE
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • UNITED KINGDOM
        • FRANCE
        • GERMANY
        • ITALY
        • RUSSIA
        • BELGIUM
        • POLAND
        • REST OF EUROPE
    • ASIA-PACIFIC
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • JAPAN
        • CHINA
        • INDIA
        • SOUTH KOREA
        • AUSTRALIA & NEW ZEALAND
        • THAILAND
        • INDONESIA
        • VIETNAM
        • REST OF ASIA-PACIFIC
    • REST OF WORLD
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • REGIONAL ANALYSIS
        • LATIN AMERICA
        • MIDDLE EAST & AFRICA
  1. COMPETITIVE LANDSCAPE
    • KEY STRATEGIC DEVELOPMENTS
      • MERGERS & ACQUISITIONS
      • PRODUCT LAUNCHES & DEVELOPMENTS
      • PARTNERSHIPS, CONTRACTS/AGREEMENTS & COLLABORATIONS
      • BUSINESS EXPANSIONS/ APPROVALS/ ANNOUNCEMENTS
    • COMPANY PROFILES
      • ADAPTIVE BIOTECHNOLOGIES
      • AGILENT TECHNOLOGIES INC
      • ANGLE PLC
      • BECTON, DICKINSON AND COMPANY (BD)
      • BIOCEPT INC
      • BIO-RAD LABORATORIES INC
      • HOFFMANN-LA ROCHE
      • FOUNDATION MEDICINE
      • GRAIL
      • GUARDANT HEALTH INC
      • ILLUMINA INC
      • MDXHEALTH SA
      • MENARINI-SILICON BIOSYSTEMS
      • MYRIAD GENETICS INC
      • NATERA
      • PERSONAL GENOME DIAGNOSTICS
      • QIAGEN NV
      • THERMO FISHER SCIENTIFIC INC

TABLE LIST

TABLE 1: MARKET SNAPSHOT – LIQUID BIOPSY

TABLE 2: GOVERNMENT INITIATIVES FOR CANCER AND LIQUID BIOPSY TESTING IN SOME COUNTRIES

TABLE 3: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 4: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 5: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 6: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 7: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 8: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 9: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 10: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 11: NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES

TABLE 12: ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS

TABLE 13: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 14: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 15: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 16: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 17: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 18: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 19: GLOBAL LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 20: GLOBAL LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 21: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 22: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 23: LEADING PLAYERS OPERATING IN NORTH AMERICA LIQUID BIOPSY MARKET

TABLE 24: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 25: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 26: LEADING PLAYERS OPERATING IN EUROPE LIQUID BIOPSY MARKET

TABLE 27: ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 28: ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 29: LEADING PLAYERS OPERATING IN ASIA-PACIFIC LIQUID BIOPSY MARKET

TABLE 30: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 31: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 32: LEADING PLAYERS OPERATING IN ASIA-PACIFIC LIQUID BIOPSY MARKET

TABLE 33: LIST OF MERGERS & ACQUISITIONS

TABLE 34: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 35: LIST OF PARTNERSHIPS AND AGREEMENTS

TABLE 36: LIST OF BUSINESS EXPANSIONS AND DIVESTITURES

FIGURE LIST

FIGURE 1: PORTER’S FIVE FORCES ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, IN 2020

FIGURE 6: GLOBAL LIQUID BIOPSY MARKET, BY LUNG CANCER, 2021-2028 (IN $ MILLION)

FIGURE 7: GLOBAL LIQUID BIOPSY MARKET, BY BREAST CANCER, 2021-2028 (IN $ MILLION)

FIGURE 8: GLOBAL LIQUID BIOPSY MARKET, BY PROSTATE CANCER, 2021-2028 (IN $ MILLION)

FIGURE 9: GLOBAL LIQUID BIOPSY MARKET, BY COLORECTAL CANCER, 2021-2028 (IN $ MILLION)

FIGURE 10: GLOBAL LIQUID BIOPSY MARKET, BY MELANOMA CANCER, 2021-2028 (IN $ MILLION)

FIGURE 11: GLOBAL LIQUID BIOPSY MARKET, BY OTHER TYPES OF CANCER, 2021-2028 (IN $ MILLION)

FIGURE 12: GLOBAL LIQUID BIOPSY MARKET, BY NON-ONCOLOGY APPLICATION, 2021-2028 (IN $ MILLION)

FIGURE 13: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, IN 2020

FIGURE 14: GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT MONITORING, 2021-2028 (IN $ MILLION)

FIGURE 15: GLOBAL LIQUID BIOPSY MARKET, BY PROGNOSIS AND REOCCURRENCE MONITORING, 2021-2028 (IN $ MILLION)

FIGURE 16: GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT SELECTION, 2021-2028 (IN $ MILLION)

FIGURE 17: GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS AND SCREENING, 2021-2028 (IN $ MILLION)

FIGURE 18: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, IN 2020

FIGURE 19: GLOBAL LIQUID BIOPSY MARKET, BY NUCLEIC ACID, 2021-2028 (IN $ MILLION)

FIGURE 20: GLOBAL LIQUID BIOPSY MARKET, BY PROTEIN, 2021-2028 (IN $ MILLION)

FIGURE 21: GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES, 2021-2028 (IN $ MILLION)

FIGURE 22: GLOBAL LIQUID BIOPSY MARKET, BY CELLS, 2021-2028 (IN $ MILLION)

FIGURE 23: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, IN 2020

FIGURE 24: GLOBAL LIQUID BIOPSY MARKET, BY NGS, 2021-2028 (IN $ MILLION)

FIGURE 25: GLOBAL LIQUID BIOPSY MARKET, BY MICROARRAY, 2021-2028 (IN $ MILLION)

FIGURE 26: GLOBAL LIQUID BIOPSY MARKET, BY PCR, 2021-2028 (IN $ MILLION)

FIGURE 27: GLOBAL LIQUID BIOPSY MARKET, BY PROTEOMICS, 2021-2028 (IN $ MILLION)

FIGURE 28: GLOBAL LIQUID BIOPSY MARKET, BY OTHER ANALYSIS PLATFORMS, 2021-2028 (IN $ MILLION)

FIGURE 29: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, IN 2020

FIGURE 30: GLOBAL LIQUID BIOPSY MARKET, BY EARLY DETECTION/SCREENING, 2021-2028 (IN $ MILLION)

FIGURE 31: GLOBAL LIQUID BIOPSY MARKET, BY THERAPY GUIDANCE, 2021-2028 (IN $ MILLION)

FIGURE 32: GLOBAL LIQUID BIOPSY MARKET, BY MONITORING, 2021-2028 (IN $ MILLION)

FIGURE 33: GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS, 2021-2028 (IN $ MILLION)

FIGURE 34: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, IN 2020

FIGURE 35: GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR DNA (CTDNA), 2021-2028 (IN $ MILLION)

FIGURE 36: GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR CELLS (CTCS), 2021-2028 (IN $ MILLION)

FIGURE 37: GLOBAL LIQUID BIOPSY MARKET, BY CELL-FREE DNA (CFDNA), 2021-2028 (IN $ MILLION)

FIGURE 38: GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES AND OTHERS, 2021-2028 (IN $ MILLION)

FIGURE 39: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, IN 2020

FIGURE 40: GLOBAL LIQUID BIOPSY MARKET, BY PHYSICIANS’ OFFICE LABORATORIES, 2021-2028 (IN $ MILLION)

FIGURE 41: GLOBAL LIQUID BIOPSY MARKET, BY HOSPITALS, 2021-2028 (IN $ MILLION)

FIGURE 42: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL DIAGNOSTIC LABORATORIES, 2021-2028 (IN $ MILLION)

FIGURE 43: NORTH AMERICA LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 44: UNITED STATES LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 45: CANADA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 46: EUROPE LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 47: UNITED KINGDOM LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 48: FRANCE LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 49: GERMANY LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 50: ITALY LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 51: RUSSIA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 52: BELGIUM LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 53: POLAND LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 54: REST OF EUROPE LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 55: ASIA-PACIFIC LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 56: JAPAN LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 57: CHINA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 58: INDIA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 59: SOUTH KOREA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 60: AUSTRALIA & NEW ZEALAND LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 61: THAILAND LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 62: INDONESIA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 63: VIETNAM LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 64: REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 65: REST OF WORLD LIQUID BIOPSY MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)

FIGURE 66: LATIN AMERICA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

FIGURE 67: MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET, 2021-2028 (IN $ MILLION)

Segmentation

  1. MARKET BY THERAPEUTIC APPLICATION
    • LUNG CANCER
    • BREAST CANCER
    • PROSTATE CANCER
    • COLORECTAL CANCER
    • MELANOMA CANCER
    • OTHER TYPES OF CANCER
    • NON-ONCOLOGY APPLICATION
  2. MARKET BY CLINICAL APPLICATION
    • TREATMENT MONITORING
    • PROGNOSIS AND REOCCURRENCE MONITORING
    • TREATMENT SELECTION
    • DIAGNOSIS AND SCREENING
  3. MARKET BY BIOMARKER TYPE
    • NUCLEIC ACID
    • PROTEIN
    • EXTRACELLULAR VESICLES
    • CELLS
  4. MARKET BY ANALYSIS PLATFORM
    • NGS
    • MICROARRAY
    • PCR
    • PROTEOMICS
    • OTHER ANALYSIS PLATFORMS
  5. MARKET BY ANALYSIS PURPOSE
    • EARLY DETECTION/SCREENING
    • THERAPY GUIDANCE
    • MONITORING
    • DIAGNOSIS
  6. MARKET BY PRODUCT
    • CIRCULATING TUMOR DNA (CTDNA)
    • CIRCULATING TUMOR CELLS (CTCS)
    • CELL-FREE DNA (CFDNA)
    • EXTRACELLULAR VESICLES AND OTHERS
  7. MARKET BY END-USER
    • PHYSICIANS’ OFFICE LABORATORIES
    • HOSPITALS
    • CLINICAL DIAGNOSTIC LABORATORIES
  8. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • UNITED STATES
        • CANADA
    • EUROPE
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • UNITED KINGDOM
        • FRANCE
        • GERMANY
        • ITALY
        • RUSSIA
        • BELGIUM
        • POLAND
        • REST OF EUROPE
    • ASIA-PACIFIC
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • JAPAN
        • CHINA
        • INDIA
        • SOUTH KOREA
        • AUSTRALIA & NEW ZEALAND
        • THAILAND
        • INDONESIA
        • VIETNAM
        • REST OF ASIA-PACIFIC
    • REST OF WORLD
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • REGIONAL ANALYSIS
        • LATIN AMERICA
        • MIDDLE EAST & AFRICA

Request Free Sample

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Choose License Type

    Get In Touch

    Inquire Before Buying

    Customization

    Inkwood Research delivers customized reports as per the client's requirement to provide them with an edge in the competitive market

    Request Customization

    RELATED REPORTS